

2023 Regular Session

SENATE BILL NO. 14

BY SENATOR BERNARD

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CONTROL DANGER SUBSTANCE. Provides relative to schedules of the Uniform Controlled Dangerous Substances Law. (8/1/23)

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1) through

3 (8), (12), (17) through (22), and (24) through (29) and (Schedule V)(D)(6), to enact

4 R.S. 40:964(Schedule I)(A)(100) and (E)(14) through (16), (Schedule IV)(B)(58),

5 and (Schedule V)(D)(7), and to repeal R.S. 40:964(Schedule IV)(C), relative to the

6 Uniform Controlled Dangerous Substances Law; to add certain substances to

7 Schedules I, IV, and V; to remove substances from Schedule IV; to provide for

8 updated structural language; and to provide for related matters.

9 Be it enacted by the Legislature of Louisiana:

10 Section 1. R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1) through (8),

11 (12), (17) through (22), and (24) through (29) and (Schedule V)(D)(6) are hereby amended

12 and reenacted and R.S. 40:964(Schedule I)(A)(100) and (E)(14) through (16), (Schedule

13 IV)(B)(58), and (Schedule V)(D)(7) are hereby enacted to read as follows:

14 §964. Composition of schedules

15 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.

16 40:962, consist of the following drugs or other substances, by whatever official

17 name, common or usual name, chemical name, or brand name designated:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

SCHEDULE I

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, or salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

* * *

(100) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl) piperazin-1-yl]-1-phenylpropan-2-ol)

* * *

E. Stimulants. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including its salts, isomers, esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible within the specific chemical designation:

(1) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the following ways:

(i) By substitution ~~in~~ **on** the phenyl ring to any extent with **an** alkyl, hydroxyl alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted ~~in~~ **on** the phenyl ring by one or more other univalent substituents.

* * *

(iii) By substitution at the 2-amino nitrogen atom with alkyl, **cycloalkyl**, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

* * *

(8) Naphthylpyrovalerone whether or not further substituted ~~in~~ **on** the naphthyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide

1 substituents, whether or not further substituted ~~in~~ on the naphthyl ring by one or
 2 more other univalent substituents or whether or not further substituted ~~in~~ on the
 3 carbon chain at the 3, 4, or 5 position with an alkyl substituent.

4 * * *

5 (14) Amineptine (7-[(10,11-dihydro-5H-dibenzo
 6 [a,d]cyclohepten-5-yl)amino]heptanoic acid)

7 (15) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-
 8 1,2,3-oxadiazol-3-ium-5-yl)carbamimidate)

9 (16) Methiopropamine (N-methyl-1-(thiophen-2-yl)propane-2-amine)

10 F. Synthetic cannabinoids. Unless specifically excepted, or contained within
 11 a pharmaceutical product approved by the United States Food and Drug
 12 Administration, or unless listed in another schedule, any material, compound,
 13 mixture, or preparation which contains any quantity of a synthetic cannabinoid found
 14 to be in any of the following individual compounds or chemical groups, or any of
 15 those individual compounds or groups which contain any synthetic cannabinoid salts,
 16 isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence
 17 of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible
 18 within the specific compounds or chemical groups:

19 (1) Adamantoylindoles: any compound containing a 3-(1-adamantoyl)indole
 20 structure, whether or not further substituted ~~in~~ on the indole ring to any extent or
 21 whether or not substituted ~~in~~ on the adamantyl ring to any extent.

22 (2) Adamantylamidoindoles: Any compound containing a N-(adamantyl)-1H-
 23 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole
 24 ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any
 25 extent.

26 (3) Benzoylindoles: any compound containing a 3-(benzoyl)indole structure,
 27 whether or not substituted ~~in~~ on the indole ring to any extent or whether or not
 28 substituted on the phenyl ring to any extent.

29 (4) Benzylindolecarboxamides: Any compound containing a

1 N-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~
 2 on the indole ring or **whether not substituted on** the phenyl ring to any extent.

3 (5) Butaldehydeamidindoles: Any compound containing a
 4 N-(1-oxobutan-2-yl)-1H-indole-3-carboxamide structure, with or without substitution
 5 ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide,
 6 ~~alkylarylhalide, cycloalkylmethyl,~~ **arylalkylhalide, cycloalkylmethyl,**
 7 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, **halide,**
 8 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
 9 tetrahydropyranylmethyl group, whether or not further substituted on the
 10 butaldehyde group to any extent.

11 (6) Cumylindolecarboxamides: Any compound containing a
 12 N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without
 13 substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
 14 halide, ~~alkylarylhalide, cycloalkylmethyl,~~ **arylalkylhalide, cycloalkylmethyl,**
 15 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, **halide,**
 16 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
 17 tetrahydropyranylmethyl group, whether or not further substituted on the phenyl
 18 group to any extent.

19 (7) Cyclohexylphenols: any compound containing a 2-(3-
 20 hydroxycyclohexyl)phenol structure, whether or not substituted ~~in~~ on the cyclohexyl
 21 ring to any extent or **whether or not substituted on** the phenyl ring to any extent.

22 (8) Cyclopropanoylindoles: any compound containing a 3-
 23 (cyclopropanoyl)indole structure, whether or not substituted ~~in~~ on the indole ring to
 24 any extent or **whether or not substituted on** the cyclopropyl ring to any extent.

25 * * *

26 (12) Hexahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic
 27 ring system **to any extent** except where contained in cannabis or cannabis resin.

28 * * *

29 (17) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole

1 structure, whether or not substituted ~~in~~ on the indole ring to any extent or whether
2 or not substituted on the naphthyl ring to any extent.

3 (18) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole
4 structure, whether or not substituted ~~in~~ on the pyrrole ring to any extent or whether
5 or not substituted on the naphthyl ring to any extent.

6 (19) Naphthylamidoindoles: any compound containing a N-(naphthyl)-1H-
7 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole
8 ring to any extent or whether or not substituted ~~in~~ on the naphthyl ring to any extent.

9 (20) Naphthylindolecarboxylates: Any compound containing a
10 naphthyl-1H-indole-3-carboxylate structure, whether or not further substituted ~~in~~ on
11 the indole ring or whether or not substituted on the naphthyl ring to any extent.

12 (21) Naphthylmethylindenes: any compound containing a 1-(1-
13 naphthylmethyl)indene structure, whether or not substituted ~~in~~ on the indene ring to
14 any extent or whether or not substituted on the naphthyl ring to any extent.

15 (22) Naphthylmethylindoles: any compound containing a 1-H-indol-3-yl-(1-
16 naphthyl)methane structure, whether or not substituted ~~in~~ on the indole ring to any
17 extent or whether or not substituted on the naphthyl ring to any extent.

18 * * *

19 (24) Phenylacetylindoles: any compound containing a 3-phenylacetylindole
20 structure, whether or not substituted ~~in~~ on the indole ring to any extent or whether
21 or not substituted on the phenyl ring to any extent.

22 (25) Phenylindolecarboxamides: Any compound containing a
23 N-phenyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~
24 on the indole ring or whether or not substituted on the phenyl ring to any extent.

25 (26) Phenylpropionaldehydeamidoindoles: Any compound containing a
26 N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without
27 substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
28 halide, ~~alkylarylhalide, cycloalkylmethyl,~~ arylalkylhalide, cycloalkylmethyl,
29 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide,

1 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
 2 tetrahydropyranylmethyl group, whether or not further substituted on the
 3 phenylpropionaldehyde group to any extent.

4 (27) Quinolinyndolecarboxamides: Any compound containing a N-
 5 quinoliny-1H-indole-3-carboxamide or N-isoquinoliny-1H-indole-3-carboxamide
 6 structure, whether or not further substituted ~~in~~ on the indole, quinoline or the
 7 isoquinoline ring to any extent.

8 (28) Quinolinyndolecarboxylates: any compound containing a
 9 quinolin-8-yl-1H-indole-3-carboxylate or isoquinolin-8-yl-1H-indole-3-carboxylate
 10 structure, whether or not further substituted ~~in~~ on the indole, quinoline, or
 11 isoquinoline ring to any extent.

12 (29) Tetrahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic
 13 ring system to any extent except where contained in cannabis or cannabis resin.

14 * * *

15 SCHEDULE IV

16 * * *

17 B. Depressants.

18 Unless specifically excepted or unless listed in another schedule, any
 19 material, compound, mixture, or preparation containing any quantity of the following
 20 substances, including its salts, isomers, and salts of isomers, whenever the existence
 21 of such salts, isomers, and salts of isomers is possible within the specific chemical
 22 designation:

23 * * *

24 **(58) Daridorexant**

25 * * *

26 SCHEDULE V

27 * * *

28 D. Depressants. Unless specifically exempted or excluded or unless listed in
 29 another schedule, any material, compound, mixture, or preparation which contains

1 any quantity of the following substances having a depressant effect on the central
2 nervous system, including its salts:

3 * * *

4 (6) ~~Pregalin~~ **Pregabalin**

5 (7) **Ganaxolone (3- α -hydroxy-3- β -methyl-5- α -pregnan-20-one)**

6 * * *

7 Section 2. R.S. 40:964(Schedule IV)(C) is hereby repealed.

8 Section 3. The Louisiana State Law Institute is hereby authorized and directed to
9 renumber the substances in R.S. 40:964(Schedule I)(A), (C), and (E), (Schedule IV)(B), and
10 (Schedule V)(D) to ensure that the substances are in alphabetical order.

The original instrument and the following digest, which constitutes no part
of the legislative instrument, were prepared by Brandi Cannon.

DIGEST

SB 14 Engrossed

2023 Regular Session

Bernard

Present law provides for the designation of controlled dangerous substances into Schedules I, II, III, IV, and V based upon the substances' potential for addiction and abuse.

Proposed law adds Zipeprol, Amineptine, Mesocarb, and Methiopropamine to Schedule I.

Proposed law adds Daridorexant to Schedule IV and removes Fenfluramine.

Proposed law adds Ganaxolone to Schedule V.

Proposed law updates the structural language for stimulants and synthetic cannabinoids in Schedule I.

Effective August 1, 2023.

(Amends R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1)-(8), (12), (17)-(22), and (24)-(29) and (Schedule V)(D)(6); adds R.S. 40:964(Schedule I)(A)(100) and (E)(14)-(16), (Schedule IV)(B)(58), and (Schedule V)(D)(7); repeals R.S. 40:964(Schedule IV)(C))

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Delete 12 proposed Schedule I substances.
2. Make technical changes.